CROI 2021: New compounds for prevention and treatment of COVID-19
Simon Collins, HIV i-Base
CROI 2021 included important results from experimental treatments that reported positive results from early interventions, especially using monoclonal antibodies. Four short reports are included below.
- Molnupiravir significantly reduced SARS-CoV-2 viral load after five days in early infection
- Bamlanivimab works as prophylaxis in high risk populations
- Bamlanivimab and etesevimab (Eli-Lilly) reduced hospitalisation and mortality in mild/moderate infection
- Casirivimab and imdevimab (Regeneron) dual mAbs reduce risk of symptomatic transmission
This report was first published on 19 March 2021.